Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02461602 · ClinicalTrials.gov registry record
Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients
A clinical trial of Atrial Fibrillation, sponsored by Duke University.
- Completed
- Registry status
- 251
- Enrollment target
- 20
- Study locations
NCT02461602: Completed study of Atrial Fibrillation, sponsored by Duke University.
NCT02461602 is a study of Atrial Fibrillation that has completed, run by Duke University. The registered enrollment target is 251 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02461602, a study of Atrial Fibrillation, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
ELITE (Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients) is a two year research project to assess warfarin management issues faced by atrial fibrillation (AF) patients in ambulatory settings.
Conditions Studied
Study Locations (20)
Florida
- Holy Cross Medical Group - Coral Springs
- Charlotte Heart Group - Port Charlotte
Georgia
- Atlanta Institute for Medical Research, Inc. - Atlanta
- Atlanta Heart Specialists - Cumming
Michigan
- Endeavor Medical Research - Alpena
- Great Lakes Heart and Vascular Institute - Saint Joseph
New Jersey
- Cardiovascular Associates of the Delaware Valley - Elmer
- Lourdes Cardiology Services - Voorhees Township
Texas
- North Texas Research Associates - Allen
- Providence Health Center - Waco
California
- Foothill Cardiology - Pasadena
Indiana
- Cardiovascular Research of Northwest Indiana, L.L.C. - Munster
Kentucky
- Research Integrity, LLC. - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-05-31 |
What the finished NCT02461602 record still lists
NCT02461602 is an observational study that tracks outcomes without assigning an intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT02461602 names 20 study sites across 15 states, led by Florida, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT02461602 about?
NCT02461602 is a clinical study titled "Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients". ELITE (Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients) is a two year research project to assess warfarin management issues faced by atrial fibrillation (AF) patients in ambulatory settings.
What is the current status of trial NCT02461602?
This trial is currently completed. The enrollment target is 251 participants. The study started on 2016-02. Estimated completion is 2018-05-31.
What conditions does trial NCT02461602 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
Who is sponsoring clinical trial NCT02461602?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02461602 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02461602's enrollment target sits among peer trials
251 91st of 202 higher than 112 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia